Intussusception Surveillance After Rotarix Introduction in Mexico

Sponsor

GlaxoSmithKline (Industry)

Overall Status

Completed

CT.gov ID

NCT00595205

Collaborator

(none)

786

Enrollment

Location

Duration (Months)

23.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

GSK Biologicals' rotavirus vaccine, Rotarix™ has been recommended for universal use targeting infants through the Expanded Program on Immunization (EPI) in Mexico. This protocol describes a Phase IV safety study in Mexico designed to further evaluate the safety profile of Rotarix™ with regard to intussusception (IS). The data generated by this study will be useful for public health officers and policy makers in confirming the safety profile of Rotarix™.

Condition or Disease	Intervention/Treatment	Phase
Intussusception (IS) Rotavirus Vaccines	Other: Hospital log review.

Detailed Description

Rationale for amendment 3:

The findings from the first year of the implementation of the active surveillance showed that most Lower Respiratory Tract-Related Post-Neonatal (LRTI) Mortality cases could not be included into the study, because most of the grieving parents refused to participate in the study. The European Medicines Agency Marketing Authorization Holders (EMEA MAH) also generated a substantial amount of additional clinical and post-marketing safety data throughout the world, which clearly indicated the absence of any safety signal when considering the LTRI-related fatalities. Therefore surveillance for LRTI mortality cases was removed from the study design. The number of sites was reduced from approximately 230 to about 60 to 90 in order to reflect the above mentioned change that reduced the need for so many sites. Additionally, passive surveillance for IS cases through the IMSS database was not feasible, due to restrictions of the IMSS internal policies and to the current limitations in the databases linkage and structure abilities.

Lastly, SAEs reporting procedures had to be adjusted according to the Council for International Organizations of Medical Sciences (CIOMS) Working Group V, 2001 publication such that there will be no expedited safety reporting for this study.

Design This is a post marketing ,Phase IV, observational, prospective, self-controlled case series, vaccine safety study including: a) hospital-based surveillance to monitor for the occurrence of IS through active surveillance; b) a self-controlled case series (SCCS) design/analysis to assess the temporal association with Rotarix™ of the IS ascertained through active surveillance.

The aim of the active hospital-based surveillance system is to identify all definite IS cases in children younger than one year of age (children ineligible on day of first birthday) among IMSS members. Surveillance will be conducted in approximately 60 to 90 IMSS health facilities with pediatric surgery service.

Study participation for children fitting the surveillance case definition of IS will include parental/guardian/legal representative interview, as well as a review of medical charts and vaccination records. Additional medical information will be collected through medical record review during hospitalization and after the child has been discharged.

Study Design

Study Type:

Observational

Actual Enrollment :

786 participants

Time Perspective:

Prospective

Official Title:

Post-Authorization Safety Study (PASS) of Post-Marketing Surveillance for Intussusception Following Rotarix™ Introduction Into the Instituto Mexicano Del Seguro Social (IMSS) in Mexico

Study Start Date :

Jan 1, 2008

Actual Primary Completion Date :

Oct 1, 2010

Actual Study Completion Date :

Oct 1, 2010

Arms and Interventions

Arm	Intervention/Treatment
Group IS Subjects <1 year of age with definite intussusception cases who had received Rotarix™.	Other: Hospital log review. Reviewing of the hospital log to monitor for the occurrence of intussusception.

Arm

Intervention/Treatment

Group IS

Subjects <1 year of age with definite intussusception cases who had received Rotarix™.

Other: Hospital log review.

Reviewing of the hospital log to monitor for the occurrence of intussusception.

Outcome Measures

Primary Outcome Measures

Occurrence of definite IS episodes within Day 0 to Day 30 following vaccination [0- 30 days following Rotarix vaccination]

Secondary Outcome Measures

Occurrence of definite IS episodes within Day 0 to Day 15 following vaccination [Day 0 to Day 15 post Rotarix vaccination]
Yearly occurrence of definite IS episodes (regardless of vaccination status) [Assessed for the interim analysis and after study conclusion]

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A to 364 Days

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

A child's clinical episode will be defined as an IS case and deemed eligible for the study if he/she meets the following criteria:

Subject is an IMSS affiliate
Subject is being treated/has been treated/has been referred for treatment at one of the IMSS hospitals/medical facilities with IS during the study period.
Male or female child is <one year of age at the time of diagnosis of the IS (child becomes ineligible on the day of their first birthday)
Subject is diagnosed with definite IS based on the Brighton criteria
Written informed consent is obtained from the parent/guardian/legal representative of the subject Subjects meeting the above criteria will be eligible for inclusion in this study regardless of whether or not the subject has had a radiographically or surgically confirmed case of IS prior to the current episode.